TAGAMET HB Drug Patent Profile
✉ Email this page to a colleague
When do Tagamet Hb patents expire, and what generic alternatives are available?
Tagamet Hb is a drug marketed by Medtech Products and Glaxosmithkline and is included in two NDAs.
The generic ingredient in TAGAMET HB is cimetidine. There are twenty-five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tagamet Hb
A generic version of TAGAMET HB was approved as cimetidine by MYLAN on May 17th, 1994.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAGAMET HB?
- What are the global sales for TAGAMET HB?
- What is Average Wholesale Price for TAGAMET HB?
Summary for TAGAMET HB
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 178 |
| Clinical Trials: | 7 |
| Patent Applications: | 5,635 |
| DailyMed Link: | TAGAMET HB at DailyMed |
Recent Clinical Trials for TAGAMET HB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Washington | Phase 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 |
| National Institutes of Health (NIH) | Early Phase 1 |
Pharmacology for TAGAMET HB
| Drug Class | Histamine-2 Receptor Antagonist |
| Mechanism of Action | Histamine H2 Receptor Antagonists |
US Patents and Regulatory Information for TAGAMET HB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtech Products | TAGAMET HB | cimetidine | TABLET;ORAL | 020238-001 | Jun 19, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Medtech Products | TAGAMET HB | cimetidine | TABLET;ORAL | 020238-002 | Aug 21, 1996 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | TAGAMET HB 200 | cimetidine | SUSPENSION;ORAL | 020951-001 | Jul 9, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
